Navigation Links
Ontario Genomics Institute invests in validation of a novel protein interaction technology at U of T
Date:11/1/2012

TORONTO, ON, Nov. 1, 2012 - Every process in a cell is affected by interactions between proteins. Understanding how proteins react in the human body and their relationship to diseases is essential to the development of new and better targeted therapies. The Ontario Genomics Institute (OGI) is providing $100,000 through its Pre-commercialization Business Development Fund (PBDF) to the University of Toronto (U of T)'s Mammalian Membrane Two-Hybrid (MaMTH) project, which seeks to develop and commercialize a process to better understand membrane proteins in mammalian cells.

Dr. Igor Stagljar and his research team at U of T have developed a technology to analyze protein-protein interactions of mammalian integral membrane proteins. Membrane proteins, which make up approximately one-third of all proteins in a cell, are responsible for a variety of processes, making them attractive therapeutic targets. However, they are difficult to study because of their chemical complexity. This translational research tool will allow researchers to study interactions between membrane proteins of interest and how they respond to various therapeutic compounds in the context of the human cell.

"This tool has the potential to improve drug development and expand the resources available to companies developing new therapeutics," said Dr. Mark Poznansky, President and CEO, Ontario Genomics Institute. "Investment in projects like Dr. Stagljar's demonstrate OGI's commitment to fostering a vibrant life sciences community in Ontario."

Proteomic technologies such as MaMTH are increasingly playing key roles in the fields of medicine, drug discovery and molecular diagnostics. This tool has garnered attention from industry, who plan to license the technology if the project is successful. OGI's funding is essential for the development and validation necessary to make this assay commercially viable.

"We are pleased to receive this funding from OGI, which comes at a critical time as we commercialize our assay," said Dr. Stagljar, Professor, U of T. "There is strong demand for technologies like MaMTH from both academia and pharmaceutical companies, and this funding will enable us to make the final step in bringing this tool to market."

"The MaMTH project is a great example of an effective partnership between researchers working with their academic institution and key strategic partners, to benefit the research community and translate a technology to industry," said Ian Stewart, Senior Manager, Commercialization and Business Development, the Innovations and Partnerships Office at U of T.

OGI's PBDF program invests in opportunities based in genomics, proteomics or associated technologies that fall in the proof-of-principle (validation) phase of research and have the short-term potential to secure a significant next step towards the marketplace. Previous recipients have included Ontario universities, research institutes and companies.


'/>"/>

Contact: Christine Beyaert
cbeyaert@ontariogenomics.ca
416-673-6597
Ontario Genomics Institute
Source:Eurekalert

Related biology news :

1. New genomics study shows ancestry could help solve disease riddles
2. Physiological Genomics journal announces a major restructuring
3. 2 pioneering plant genomics efforts given a funding boost by National Science Foundation
4. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
5. Elsevier launches new open access journal: Applied and Translational Genomics
6. The genomics symposium to boost the further development of cancer research
7. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
8. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
9. BGI, University of Helsinki and Wuhan University sign a MOU concerning cooperation on genomics
10. SDSCs big data expertise aiding genomics research
11. Reducing radiation: Heart Institute model shows hope for new standards worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology: